Secondary Prophylaxis With GCSF May Help Maintain Chemo Dose-Intensity

Share this content:
Secondary prophylaxis with granulocyte colony-stimulating factor showed a statistically significant improvement.
Secondary prophylaxis with granulocyte colony-stimulating factor showed a statistically significant improvement.

Secondary prophylaxis with granulocyte colony-stimulating factor (GCSF) showed a statistically significant improvement in the achievement of adequate relative dose intensity (RDI) in non-intensive chemotherapy regimens, a new study published online ahead of print in the journal Annals of Oncology has shown.1

Because data have suggested that achievement of planned dose intensity may impact survival, researchers sought to compare GCSF with standard management following a first neutropenic event in achieving planned dose intensity.

For the study, researchers enrolled 407 adult patients receiving adjuvant or neoadjuvant chemotherapy for early breast cancer. Most regimens were anthracycline-based, which may have included a sequential taxane and/or were in clinical trials.

Following a first neutropenic event, defined as hospitalization due to neutropenic fever, an ANC < 1.5 x 109/L requiring treatment delay, or dose reduction of ≥15% of planned dose, participants were randomly assigned to receive filgrastim for 7 days or pegfilgrastim as secondary prophylaxis or standard care.

RELATED: Favorable Gene Expression May Signify Low Rates of HER2-Negative Breast Cancer Recurrence

Results showed that 75% of patients in the GCSF arm achieved 85% planned RDI compared with 50% of patients in the control arm (P<0.0001). Researchers also found that secondary prophylaxis was associated with a reduction in post-randomization neutropenic events, which occurred in 18.2% of the GCSF arm and 65.7% of controls.

“This may have important clinical implications for outcome,” the authors concluded.

Reference

  1. Leonard RCF, Mansi JL, Keerie C, et al. A randomised trial of secondary prophylaxis using granulocyte colony stimulating factor (‘SPROG' Trial) for maintaining dose-intensity of standard adjuvant chemotherapy for breast cancer – by the Anglo-Celtic Cooperative Group and NCRN [published online ahead of print September 28, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv389.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs